Cargando…

Plasma soluble PD-L1 and STAT3 predict the prognosis in diffuse large B cell lymphoma patients

Purpose: Diffuse large B cell lymphoma (DLBCL) is one of the most common B cell lymphomas, which displays heterogeneous pathologies. Programmed cell death 1/ programmed cell death ligand 1 (PD-1/PD-L1) plays an essential role in immunosuppression in multiple malignancies. Signal transducer and activ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fei, Yue, Yu, Jingwei, Li, Yang, Li, Linyu, Zhou, Shiyong, Zhang, Tingting, Li, Lanfang, Qiu, Lihua, Meng, Bin, Pan, Yi, Ren, Xiubao, Qian, Zhengzi, Wang, Xianhuo, Zhang, Huilai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7591999/ https://www.ncbi.nlm.nih.gov/pubmed/33123290 http://dx.doi.org/10.7150/jca.47816

Ejemplares similares

Screening of Adverse Prognostic Factors and Construction of Prognostic Index in Previously Untreated Concurrent Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
por: Qu, Zhenjie, et al.
Publicado: (2022)

PIM1 genetic alterations associated with distinct molecular profiles, phenotypes and drug responses in diffuse large B‐cell lymphoma
por: Zhang, Huilai, et al.
Publicado: (2022)

A novel prognostic signature based on immune-related genes of diffuse large B-cell lymphoma
por: Wu, Zizheng, et al.
Publicado: (2021)

Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T‐cell lymphomas
por: Zhang, Xuhan, et al.
Publicado: (2019)

Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL
por: Zhang, Tingting, et al.
Publicado: (2022)

Clinical features and outcomes of patients with follicular lymphoma: A real-world study of 926 patients in China
por: Gao, Fenghua, et al.
Publicado: (2022)

Biomimetic black phosphorus quantum dots-based photothermal therapy combined with anti-PD-L1 treatment inhibits recurrence and metastasis in triple-negative breast cancer
por: Zhao, Peiqi, et al.
Publicado: (2021)

Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3(+) CD8(+) T Cells and Survival in Diffuse Large B Cell Lymphoma
por: Zhang, Tingting, et al.
Publicado: (2020)

Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells
por: Dong, Ling, et al.
Publicado: (2016)

m6A-Regulator Expression Signatures Identify a Subset of Follicular Lymphoma Harboring an Exhausted Tumor Microenvironment
por: Zhang, Tingting, et al.
Publicado: (2022)

Corrigendum to “Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3(+) CD8(+) T Cells and Survival in Diffuse Large B Cell Lymphoma”
por: Zhang, Tingting, et al.
Publicado: (2021)

Programmed Cell Death Protein 1/Programmed Cell Death Ligand-1 Axis activates Intracellular ERK Signaling in Tumor Cells to Mediate Poor Prognosis in T-cell Lymphoma
por: Li, Yang, et al.
Publicado: (2021)

Bortezomib enhances the anti-cancer effect of the novel Bruton’s tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK
por: Wang, Xianhuo, et al.
Publicado: (2021)

An Immune-Clinical Prognostic Index (ICPI) for Patients With De Novo Follicular Lymphoma Treated With R-CHOP/CHOP Chemotherapy
por: Lu, Yaxiao, et al.
Publicado: (2021)

A modified prognostic model in patients with diffuse large B-cell lymphoma treated with immunochemotherapy
por: Zhao, Peiqi, et al.
Publicado: (2021)

Pan-Cancer Analysis Reveals Genomic and Clinical Characteristics of TRPV Channel-Related Genes
por: Wang, Xiaoxuan, et al.
Publicado: (2022)

A retrospective analysis of EBV‐DNA status with the prognosis of lymphoma
por: Qiu, Lihua, et al.
Publicado: (2022)

A 9-LncRNA Signature for Predicting Prognosis and Immune Response in Diffuse Large B-Cell Lymphoma
por: Wang, Xiaoxuan, et al.
Publicado: (2022)

Cancer Cell Membrane Camouflaged Mesoporous Silica Nanoparticles Combined with Immune Checkpoint Blockade for Regulating Tumor Microenvironment and Enhancing Antitumor Therapy
por: Zhao, Peiqi, et al.
Publicado: (2021)

Overexpression of microRNA-130a predicts adverse prognosis of primary gastrointestinal diffuse large B-cell lymphoma
por: Chen, Leiyuan, et al.
Publicado: (2020)

Hybrid Membrane Nanovaccines Combined with Immune Checkpoint Blockade to Enhance Cancer Immunotherapy
por: Zhao, Peiqi, et al.
Publicado: (2022)

Gemcitabine, Navelbine, and Doxorubicin as Treatment for Patients with Refractory or Relapsed T-Cell Lymphoma
por: Qian, Zhengzi, et al.
Publicado: (2015)

A Phase I Trial to Evaluate the Multiple-Dose Safety and Antitumor Activity of Ursolic Acid Liposomes in Subjects with Advanced Solid Tumors
por: Qian, Zhengzi, et al.
Publicado: (2015)

miR-150 is a negative independent prognostic biomarker for primary gastrointestinal diffuse large B-cell lymphoma
por: Wang, Xinyuan, et al.
Publicado: (2020)

Characteristics and outcomes of non-Hodgkin’s lymphoma patients with leptomeningeal metastases
por: Meng, Xiangrui, et al.
Publicado: (2018)

Expression of PD-L1 and YWHAZ in Patients with Diffuse Large B Cell Lymphoma: A Possible Association with the Prognosis of Lymphoma
por: Yan, Shufang, et al.
Publicado: (2022)

S216: CD47/PD-L1 BISPECIFIC ANTIBODY (IBI322) IN ANTI-PD-1 OR PD-L1 TREATMENT-RESISTANT CLASSICAL HODGKIN LYMPHOMA: A PHASE I STUDY
por: Zhang, Huilai, et al.
Publicado: (2023)

miR-10a inhibits cell proliferation and promotes cell apoptosis by targeting BCL6 in diffuse large B-cell lymphoma
por: Fan, Qian, et al.
Publicado: (2016)

Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma
por: Kwon, Hyun Jung, et al.
Publicado: (2018)

Distinct clinical and genetic features of hepatitis B virus–associated follicular lymphoma in Chinese patients
por: Ren, Weicheng, et al.
Publicado: (2022)

Soluble PD-1 but Not PD-L1 Levels Predict Poor Outcome in Patients with High-Risk Diffuse Large B-Cell Lymphoma
por: Vajavaara, Heli, et al.
Publicado: (2021)

Anti-PD1 up-regulates PD-L1 expression and inhibits T-cell lymphoma progression: possible involvement of an IFN-γ-associated JAK-STAT pathway
por: Xue, Weili, et al.
Publicado: (2019)

High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma
por: ZL, Wu, et al.
Publicado: (2011)

A Novel Defined Super-Enhancer Associated Gene Signature to Predict Prognosis in Patients With Diffuse Large B-Cell Lymphoma
por: Xu, Hong, et al.
Publicado: (2022)

Genetic polymorphisms of STAT3 correlated with prognosis in diffuse large B-cell lymphoma patients treated with rituximab
por: Hu, Yunfei, et al.
Publicado: (2014)

Genetic polymorphism and transcriptional regulation of CREBBP gene in patient with diffuse large B-cell lymphoma
por: Zhao, Haifeng, et al.
Publicado: (2019)

Genome-wide mutational signatures revealed distinct developmental paths for human B cell lymphomas
por: Ye, Xiaofei, et al.
Publicado: (2020)

Hydrogen solubility and diffusivity at Σ3 grain boundary of PdCu
por: Liu, L. C., et al.
Publicado: (2021)

Effect of immunodeficiency and tumor marker expression on HIV-related diffuse large B-cell lymphoma prognosis
por: Silverberg, Michael J, et al.
Publicado: (2012)

Expression and Prognostic Significance of PD-L2 in Diffuse Large B-Cell Lymphoma
por: Gu, Qianhui, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cf3mfhhpsh8a57a36s4vu21t5i